3SBio's (HKG:1530) subsidiary Shenyang Sunshine Pharmaceutical will obtain the exclusive commercialization rights of Shanghai RMX Biopharma's product of paclitaxel oral solution in Hong Kong and China, a Thursday Hong Kong bourse filing said.
Shenyang Sunshine will make an upfront payment to RMX Biopharma, a subsidiary of Shanghai Haihe Biopharma Research and Development, as well as milestone payments for sales and research and development.
The ongoing research, development and any related clinical and registration works will still be handled by RMX Biopharma.
The biopharmaceutical company's shares were down over 1% on Thursday's close.
Price (HKD): $6.20, Change: $-0.090, Percent Change: -1.43%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。